Souhaitez-vous accéder aux communiqués récents ?

- Evotec Reports Strong Profitable Growth in H1 2012 With Revenues Up 26% and a Positive Operating Result of €1.3 M - New CureBeta Pharma Collaboration Through EVT Innovate Initiative...

HAMBURG, Germany, Aug. 2, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) will report its financial results for the first half of 2012 on Wednesday, 8 August 2012. The Company is going...

HAMBURG, Germany, July 10, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has licensed to Janssen Pharmaceuticals, Inc. a portfolio of small molecules and...

HAMBURG, Germany, June 5, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that its research alliance with Boehringer Ingelheim has reached a milestone triggering a payment...

HAMBURG, Germany, May 16, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) is proud to announce the addition of Agilent Technologies' RapidFire Mass Spectrometry analysis capabilities to...

33% Revenue Growth New Pharma Collaborations Through Growth Initiatives Guidance 2012 Confirmed HAMBURG, Germany, May 10, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX)...

Evotec and 4-Antibody Launch New High Content Screening Platform for Early Antibody Functionality Testing Novel Screening Process Integrates 4-Antibody Discovery Platform and Offers Evotec...

HAMBURG, Germany, May 4, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) will report its financial results for the first quarter of 2012 on Thursday, 10 May 2012. The Company is going to...

HAMBURG, Germany, May 3, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that Evotec has entered into a multi-year compound management agreement with the United States EPA....

License Granted to One of the Largest Pharmaceutical Companies in China Development of Evotec Proprietary Compound EVT 401 Intended for Inflammatory Diseases Upfront, Approx. € 60...